Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

被引：1
|
作者：
Andre, Thierry
Bonnetain, Franck
Mineur, Laurent
Bennouna, Jaafar
Desrame, Jerome
Faroux, Roger
Dauba, Jerome
Vernerey, Dewi
Aissat, Nasredine
Louvet, Christophe
Lepere, Celine
Dupuis, Olivier Jean Marie
Becouarn, Yves
Mabro, May
Egreteau, Joelle
Bouche, Olivier
Deplanque, Gael
Ychou, Marc
De Gramont, Aimery
Taieb, Julien
机构：
[1] Hop St Antoine, APHP, Dept Med Oncol, Paris, France
[2] Univ Hosp Besancon, Dept Oncol, Methodol & Qual Life Unit, INSERM,UMR 1098, Besancon, France
[3] French Natl Platform Qual Life & Canc, Besancon, France
[4] Inst St Catherine, Avignon, France
[5] Inst Cancerol Ouest, Nantes, France
[6] Hop Prive Jean Mermoz, Lyon, France
[7] Ctr Hosp Dept Oudairies, La Roche Sur Yon, France
[8] Hop Layne, Dept Gastroenterol, Mt De Marsan, France
[9] CHRU Besancon, Methodol & Qual Life Oncol Unit, Besancon, France
[10] GERCOR, Paris, France
[11] Inst Mutualiste Montsouris, Paris, France
[12] Hop Europeen Georges Pompidou, Paris, France
[13] Clin Victor Hugo, Le Mans, France
[14] Inst Bergonie, Bordeaux, France
[15] Hop Foch, Suresnes, France
[16] Ctr Hosp Bretagne Sud, Lorient, France
[17] CHU Robert Debre, Reims, France
[18] CHU Vaudois, Med Oncol, Lausanne, Switzerland
[19] Inst Reg Canc Montpellier, Montpellier, France
[20] Franco British Inst, Levallois Perret, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3500
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A Case of Liver Fibrosis with Splenomegaly after Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer
    Kang, Gu Hyum
    Moon, Hee Seok
    Lee, Eaum Seok
    Kim, Seok Hyun
    Sung, Jae Kyu
    Lee, Byung Seok
    Jeong, Hyun Yong
    Lee, Heon Young
    Kang, Dae Young
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (12) : 1835 - 1838
  • [42] Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study
    Boyle, Jemma M.
    Kuryba, Angela
    Cowling, Thomas E.
    van der Meulen, Jan
    Fearnhead, Nicola S.
    Walker, Kate
    Braun, Michael S.
    Aggarwal, Ajay
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (02) : 335 - 346
  • [43] phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study
    Kotaka, M.
    Ishibashi, K.
    Satake, H.
    Tsuji, Y.
    Kataoka, M.
    Nakamura, M.
    Nagata, N.
    Sakamoto, J.
    Oba, K.
    Mishima, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S101 - S101
  • [44] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
    Keiichiro Ishibashi
    Toru Aoyama
    Masahito Kotaka
    Hironaga Satake
    Yasushi Tsuji
    Masato Kataoka
    Masato Nakamura
    Naoki Nagata
    Junichi Sakamoto
    Koji Oba
    Hideyuki Mishima
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 665 - 672
  • [45] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
    Ishibashi, Keiichiro
    Aoyama, Toru
    Kotaka, Masahito
    Satake, Hironaga
    Tsuji, Yasushi
    Kataoka, Masato
    Nakamura, Masato
    Nagata, Naoki
    Sakamoto, Junichi
    Oba, Koji
    Mishima, Hideyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (05) : 665 - 672
  • [46] SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer
    Han, Xiaohong
    Wang, Zheng
    Zhang, Lei
    Shen, Yinchen
    Tan, Qiaoyun
    Sun, Yongkun
    Wang, Jianfei
    Qian, Xiaoyan
    Yang, Hongying
    Shi, Yuankai
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (04): : 1522 - +
  • [47] Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
    Kotaka, Masahito
    Yamanaka, Takeharu
    Yoshino, Takayuki
    Manaka, Dai
    Eto, Tetsuya
    Hasegawa, Junichi
    Takagane, Akinori
    Nakamura, Masato
    Kato, Takeshi
    Munemoto, Yoshinori
    Nakamura, Fumitaka
    Bando, Hiroyuki
    Taniguchi, Hiroki
    Gamoh, Makio
    Shiozawa, Manabu
    Saji, Shigetoyo
    Maehara, Yoshihiko
    Mizushima, Tsunekazu
    Ohtsu, Atsushi
    Mori, Masaki
    ESMO OPEN, 2018, 3 (03)
  • [48] A statewide evaluation of adjuvant chemotherapy for stage III colon cancer.
    Petrelli, N. J.
    Grubbs, S. S.
    Spellman, J. E.
    English, C. L.
    Shevock, A.
    Nunley, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Real-world tolerance and outcomes to oxaliplatin-based adjuvant chemotherapy for stage III colon cancer - Does dose intensity matter?
    Yoon, Robert
    Wilkinson, Kate
    Gabriel, Gabriel
    Kaadan, Nasreen
    Roberts, Tara
    Lim, Stephanie
    Ray, Asghari
    Lee, Cheok Soon
    Chua, Wei
    Ng, Weng
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 132 - 133
  • [50] Considerations regarding an updated meta-analysis of the optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer
    Pang, Huayang
    Yan, Menghua
    Chen, Lihui
    Zhao, Zhou
    Li, Wei
    Zhang, Shouru
    Sun, Hao
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (07) : 4431 - 4432
12345